Clinical trials: Severe Persistent Asthma
Asthma
Dose Finding Study for QAW039 in Asthma
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy.
- Trial name
- NCT01437735
- Testing
- QAW039, Montelukast
- Where
- 206 sites in United States, Argentina and 20 more
- Volunteers
- 1,043 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with…
- Trial name
- PROSE (NCT01430403)
- Testing
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS)
- Where
- 8 sites in United States
- Volunteers
- 478 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)
The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.
- Trial name
- NCT00480649
- Testing
- Salmeterol/ fluticasone propionate
- Where
- 12 sites in South Korea
- Volunteers
- 424 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma Atopic, Asthma Severe Persistent Uncontrolled
Expression of TSLP Isoforms in Asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, leading to variable airflow obstruction, bronchial hyperresponsiveness, excessive mucus secretion, and, consequently, structural airway remodeling.
- Trial name
- NCT07786870
- Testing
- No Intervention: Observational Cohort
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Bronchial, Bronchial Asthma
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
- Trial name
- NCT00189722
- Testing
- Tacrolimus
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 160 people
- Sponsor
- Astellas Pharma Inc
Asthma
Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma
The aim of the study is to evaluate, comparatively to a placebo, the activity of oral AB1010, administered at three dose levels during 4 months to patients with severe persistent corticosteroid dependent asthma, assessed on : the…
- Trial name
- NCT00842270
- Testing
- AB1010
- Volunteers
- 44 people
- Sponsor
- AB Science
Asthma
Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma
Cross-over study to evaluate the effect on trough FEV1 after 4 weeks treatment with CHF5188 pMDI qd in adult patients with persistent asthma
- Trial name
- NCT01070524
- Testing
- CHF 5188 pMDI, Budesonide extrafine pMDI, Seretide(r) Evohaler(r)
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Withania Somnifera for Moderate-to-Severe Persistent Asthma
This randomized, double-blind, placebo-controlled study evaluated Withania somnifera root powder as a complementary therapy in adults with moderate-to-severe persistent asthma receiving standard asthma treatment.
- Trial name
- WISTA (NCT07787507)
- Testing
- Withania somnifera Root Powder, Standard Asthma Treatment
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Aligarh Muslim University
Asthma
Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) and allogeneic, interferon-γ…
- Trial name
- NCT05035862
- Testing
- Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Respiratory Tract Infections, Pediatric Respiratory Diseases
Bacterial Lysate In Preventing Asthma
Bronchiolitis is a common viral infection of the small airways of infants and some affected infants will require hospital admission.
- Conditions
- Respiratory Tract Infections, Pediatric Respiratory Diseases, Wheezing
- Trial name
- BLIPA (NCT05064631)
- Testing
- Bacterial Lysate
- Where
- 3 sites in United Kingdom
- Volunteers
- 173 people
- Sponsor
- Queen Mary University of London
Asthma
Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a protective role in patients with moderate to severe asthma.
- Trial name
- NCT00280683
- Testing
- L-arginine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Asthma
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
- Trial name
- NCT00330070
- Testing
- IPL512,602 20 mg once daily
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Inflazyme Pharmaceuticals Ltd
Asthma, Severe Persistent Asthma
Severe Asthma Research Program - Wake Forest University
The mission of SARP is to improve the understanding of severe asthma through the integrated study of the effect of genetics on the clinical and biological features of asthma and to investigate how these change over time.
- Trial name
- SARP3 (NCT01750411)
- Where
- 2 sites in United States
- Volunteers
- 87 people
- Sponsor
- Wake Forest University
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in severe asthma patients.
- Trial name
- NCT02443298
- Testing
- risankizumab
- Where
- 65 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- AbbVie